open access

Vol 64, No 4 (2006)
Other
Published online: 2006-04-27
Submitted: 2012-12-28
Get Citation

ORIGINAL ARTICLE
Cytochrome P450 2C9 polymorphism and acenocoumarol therapy

Grzegorz Dzida
Kardiol Pol 2006;64(4):397-402.

open access

Vol 64, No 4 (2006)
Other
Published online: 2006-04-27
Submitted: 2012-12-28

Abstract


Background:
Oral anticoagulants, in Hungary acenocoumarol being the one exclusively used, have a low therapeutic index and a high bleeding complication rate. The cytochrome P450 2C9 enzyme plays an important role in their metabolism.
Aim:
To investigate the influence of CYP2C9 polymorphism on the occurrence of bleeding complications related to acenocoumarol therapy.
Methods:
Genotyping of 421 patients (183 men and 238 women, mean age 66.2±11.8 years), who had been taking acenocoumarol for at least 6 months, was performed. Based on patient history and laboratory data, the correlations between genotype and acenocoumarol dose and bleeding complications were retrospectively analysed.
Results:
In 145 patients bearing alleles with reduced activity (CYP2C9*2 and/or *3), the optimal dose of acenocoumarol was significantly (p

Abstract


Background:
Oral anticoagulants, in Hungary acenocoumarol being the one exclusively used, have a low therapeutic index and a high bleeding complication rate. The cytochrome P450 2C9 enzyme plays an important role in their metabolism.
Aim:
To investigate the influence of CYP2C9 polymorphism on the occurrence of bleeding complications related to acenocoumarol therapy.
Methods:
Genotyping of 421 patients (183 men and 238 women, mean age 66.2±11.8 years), who had been taking acenocoumarol for at least 6 months, was performed. Based on patient history and laboratory data, the correlations between genotype and acenocoumarol dose and bleeding complications were retrospectively analysed.
Results:
In 145 patients bearing alleles with reduced activity (CYP2C9*2 and/or *3), the optimal dose of acenocoumarol was significantly (p
Get Citation

Keywords

oral anticoagulants; acenocoumarol; cytochrome P450

About this article
Title

ORIGINAL ARTICLE
Cytochrome P450 2C9 polymorphism and acenocoumarol therapy

Journal

Kardiologia Polska (Polish Heart Journal)

Issue

Vol 64, No 4 (2006)

Pages

397-402

Published online

2006-04-27

Bibliographic record

Kardiol Pol 2006;64(4):397-402.

Keywords

oral anticoagulants
acenocoumarol
cytochrome P450

Authors

Grzegorz Dzida

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., Świętokrzyska 73 street, 80–180 Gdańsk, Poland

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl